All In Biotech

Drug Trial Radar · NCT07677683

STP705 Injection for Submental Fat Reduction

A Phase 2 Study of STP705 Injection for Submental Fat Reduction

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Jul 25, 2027

Study completion Sep 25, 2027

Sponsor

Lead sponsor
SirnaomicsIndustry
Sponsor type
Industry
Collaborators
Emeritus Research
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study aims to assess the efficacy of SC injections of STP705 for the reduction of Submental fat in apopulation of healthy adult volunteers, and to further establish its safety and tolerability. The primary objective is to evaluate the efficacy of STP705 injection for Submental fat reduction. The second objective is to evaluate the safety and tolerability of STP705 injection. This is an open-label study. Eligible participants will be sequentially enrolled into 1 of 3 treatment cohorts, as follows: Cohort 1: 40 µg STP705 per injection. Up to 280 µg in total (n = 10 participants) Cohort 2: 64 µg STP705 per injection. Up to 448 µg in total (n = 10 participants) Cohort 3: 80 µg STP705 per injection. Up to 560 µg in total (n = 10 participants) The STP705 powder will be reconstituted with dextrose 5% in water (D5W). A total of 7 injections (3.5 mL total volume) in a single treatment may be administered to each participant in the submental triangle area (ie, for a total dose of up to 280 µg, 448 µg or 560 µg STP705 for each cohort). The Submental fat injections will be performed at Day 1/Baseline, Day 29, and Day 57 , pending favourable reviews by the Investigator of injection site reactions (ISRs), local skin reactions (LSRs), and participant assessments of the injection sites (pain, stinging, and burning). To proceed with treatment at Day 29 or Day 57, the following factors will be considered: 1. the total tolerability score per injection site (defined as the sum of the "Investigator assessed LSRscores" and the "participant-reported scores of injection site pain and stinging/burning" measured prior totreatment must be \< 6, and 2. there are no findings (eg, systemic and/or local adverse events \[AEs\]) that would preclude treatment, in the opinion of the Investigator. The tolerability score threshold should be interpreted in conjunction with clinical judgment. If condition a) is not met, participants with a total tolerability score = 6 will not be injected with the study medications. After the 3rd injection, the participant will be followed for 1 month (through to Day 85). To proceed with dose escalation (ie, from Cohort 1 to Cohort 2 or from Cohort 2 to Cohort 3), the last participant in the previous dose cohort must have completed at least 7 days of postdose safety follow-up after the first injection, and available safety data will be reviewed by the Sponsor and Medical Monitor. The decision to escalate dose will be made upon review of all data by the Medical Monitor and the Sponsor and recommendation by the Sponsor.

Conditions

  • Submental Fullness

Interventions

  • STP705Drug

    The investigational product (IP) in this study, STP705, targets 2 key proteins that play a key role in inflammation and remodelling of adipose tissue: transforming growth factor beta 1 (TGF-β1) and cyclooxygenase 2 (COX-2). TGF-β1 influences the release of inflammation mediators and promotes remodelling and collagen deposition in adipose tissue. In addition, the COX-2 gene has been shown to be highly expressed and elevated in adipose tissue under morbid obesity conditions, and COX-2 activation is a key factor contributing to the inflammation associated with obesity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The efficacy of STP705 injection for SMF reductionTime frame: From baseline to day85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emeritus Research Sydney

    Sydney, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.